SHELTON, Conn., Nov. 7, 2016
/PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the
"Company"), reports that its President Dr. Anil Diwan was recently
invited to participate in certain pharmaceutical industry meetings
to comment on regulatory aspects of nanomedicines.
On September 21, 2016, Dr. Anil
Diwan, President and Chairman of the Company, was invited as panel
participant to discuss "Regulatory Landscape: What's Needed to
Drive Innovation" in the "Anti-Infectives-Rx 2016" Conference
organized by Boston Biotech Conferences and held at the
Harvard Medical School - Joseph B.
Martin Conference Center, Boston,
MA.
On September, 19, 2016, Dr. Diwan was invited to present two
talks at the "Public Health and Emerging Microbial Threats, 14th
Annual International Conference" (PHEMT), held at the Albany College of Pharmacy and Health Sciences,
Albany, NY 12208, USA.
Dr. Diwan presented a talk entitled "Beyond Antibodies: Chemical
Nanomachines to Combat Emerging Virus Threats" about the
Nanoviricides technology and accomplishments in the first session
at PHEMT.
Additionally, Dr. Diwan was invited to and presented a talk on
"Nanomedicine Drug Development Regulatory Processes: Critical
Issues" in the second session at PHEMT. He discussed that
fundamentally nanomedicines were no different in terms of
regulatory requirements, namely, safety, efficacy, and product
quality. He further illuminated that, in contrast to small
chemicals, the complex nature of nanomedicines requires
significantly extensive work to develop manufacturing processes and
characterization methods to meet the criterion of being able to
produce a nanomedicine that will be equivalent from batch to batch.
He also discussed how the scientists, mainly chemists and
engineers, need to harness knowledge from various disciplines in
order to build quality into nanomedicines manufacture.
The PHEMT conference was co-chaired by Raj Bawa, MS, PhD, Bawa
Biotech LLC, Ashburn, VA and
Adjunct Professor, Rensselaer Polytechnic
Institute, Troy, NY; and
Shaker A. Mousa, PhD, MBA, Vice Provost and Professor, Albany College of Pharmacy and Health Sciences,
Albany, NY and Chairman &
Executive Vice President, The Pharmaceutical Research Institute,
Rensselaer, NY.
About NanoViricides:
NanoViricides, Inc. (www.nanoviricides.com) is a development stage
company that is creating special purpose nanomaterials for
antiviral therapy. The Company's novel nanoviricide® class of drug
candidates are designed to specifically attack enveloped virus
particles and to dismantle them. The Company is developing drugs
against a number of viral diseases including VZV, oral and genital
Herpes, viral diseases of the eye including EKC and herpes
keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV,
Hepatitis C, Rabies, Dengue fever, and Ebola virus, among
others.
This press release contains forward-looking statements that
reflect the Company's current expectation regarding future events.
Actual events could differ materially and substantially from those
projected herein and depend on a number of factors. Certain
statements in this release, and other written or oral statements
made by NanoViricides, Inc. are "forward-looking statements" within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. You should not
place undue reliance on forward-looking statements since they
involve known and unknown risks, uncertainties and other factors
which are, in some cases, beyond the Company's control and which
could, and likely will, materially affect actual results, levels of
activity, performance or achievements. The Company assumes no
obligation to publicly update or revise these forward-looking
statements for any reason, or to update the reasons actual results
could differ materially from those anticipated in these
forward-looking statements, even if new information becomes
available in the future. Important factors that could cause actual
results to differ materially from the company's expectations
include, but are not limited to, those factors that are disclosed
under the heading "Risk Factors" and elsewhere in documents filed
by the company from time to time with the United States Securities
and Exchange Commission and other regulatory authorities.
Although it is not possible to predict or identify all such
factors, they may include the following: demonstration and proof of
principle in pre-clinical trials that a nanoviricide is safe and
effective; successful development of our product candidates; our
ability to seek and obtain regulatory approvals, including with
respect to the indications we are seeking; the successful
commercialization of our product candidates; and market acceptance
of our products.
Logo -
http://photos.prnewswire.com/prnh/20150107/167444LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nanoviricides-president-dr-diwan-gave-invited-talks-on-regulatory-aspects-of-nanomedicines-300358162.html
SOURCE NanoViricides, Inc.